Klotz, L. 2012. Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. Canadian Urological Association Journal. 1, 2S (Dec. 2012). DOI:https://doi.org/10.5489/cuaj.70.